The study was led by Dr. Aaron Besterman, a child and adolescent psychiatrist and the Medical Director of Family Health Centers of San Diego’s Laura Rodriguez Research Institute. The research team analyzed results from 31 studies, representing more than 20,000 participants, making it one of the largest meta-analyses to date of genetic testing in schizophrenia.
The analysis found that modern genetic testing, including chromosomal microarray and exome or genome sequencing, identified a clinically significant genetic explanation for schizophrenia in about 6% of patients, or roughly 1 in 16 individuals. Early age of onset and the presence of co-occurring neurodevelopmental disorders were associated with a higher likelihood of finding a genetic explanation. When a genetic explanation is identified, it may help inform clinical management and guide family decision-making. These findings primarily reflect rare, higher-impact genetic variants detectable through current clinical testing. However, a much larger proportion of schizophrenia risk is thought to arise from the combined effects of many common genetic variants, which are not captured by standard clinical tests.
At the same time, the authors also identified important gaps in the existing evidence that are relevant to community mental health settings. Most published studies were conducted in a limited number of regions, with no data from Latin America, South Asia, or Africa, raising concerns about how well findings generalize across diverse populations. The authors also note that genetic testing has been adopted more slowly in schizophrenia than in other areas of medicine. Patient access to potentially beneficial information can contribute to ongoing health disparities.
“For a condition as complex as schizophrenia, genetics will never provide all the answers—but this study shows that for a meaningful subset of patients, modern genetic testing can offer clinically useful information, said Dr. Besterman. “The challenge now is ensuring these tools are used thoughtfully and equitably in real-world mental health settings and that mental health clinicians understand who to meaningfully leverage genetics to support their patients.” In an accompanying commentary, experts note that these findings provide an important foundation for future research and clinical integration of genetic testing in schizophrenia.
The full article can be read in Biological Psychiatry : https://www.biologicalpsychiatryjournal.com/article/S0006-3223(25)01485-4/fulltext
###
About Family Health Centers of San Diego Family Health Centers of San Diego provides caring, affordable, high-quality health care and supportive services to everyone, with a special commitment to the uninsured, low-income, and medically underserved. It is one of the nation’s largest Federally Qualified Health Centers, operating more than 90 sites across San Diego County. For more information, please visit www.fhcsd.org.
Media or community relations contact: Pauline Lucatero MSN, RN, VP Community Affairs paulinel@fhcsd.org
Biological Psychiatry
New Study Finds Genetic Testing Identifies Clinically Relevant Findings in 1 in 16 Patients with Schizophrenia